Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM)

被引：0
|
作者：
Nishikawa, Ryo
Saran, Frank
Mason, Warren
Wick, Wolfgang
Cloughesy, Timothy Francis
Henriksson, Roger
Hilton, Magalie
Garcia, Josep
Vogt, Tobias
Pallaud, Celine
Chinot, Oliver L.
机构：
[1] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Heidelberg Univ, Med Ctr, Heidelberg, Germany
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Reg Canc Ctr, Stockholm, Sweden
[7] Umea Univ Hosp, Stockholm, Sweden
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Aix Marseille Univ, CHU Timone, AP HM, Serv Neurooncol, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2023
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SAFETY RESULTS FROM AVAglio, A PHASE III RANDOMIZED STUDY OF BEVACIZUMAB (BEV) PLUS STANDARD COMBINATION TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Saran, Frank
    Chinot, Olivier L.
    Henriksson, Roger
    Mason, Warren
    Wick, Wolfgang
    Nishikawa, Ryo
    Dahr, Sunita
    Hilton, Magalie
    Garcia, Josep
    Cloughesy, Timothy
    [J]. NEURO-ONCOLOGY, 2013, 15 : 127 - 128
  • [2] Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB])
    Phillips, Heidi
    Sandmann, Thomas
    Li, Congfen
    Cloughesy, Timothy Francis
    Chlnot, Olivier L.
    Wick, Wolfgang
    Nishikawa, Ryo
    Mason, Warren P.
    Henriksson, Roger
    Saran, Frank
    Lai, Albert
    Moore, Nicola
    Hegde, Priti S.
    Abrey, Lauren E.
    Bourgon, Richard
    Garcia, Josep
    Bais, Carlos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RT) in newly diagnosed glioblastoma: final results from AVAglio
    Chinot, O.
    Cloughesy, T.
    Henriksson, R.
    Saran, F.
    Mason, W.
    Nishikawa, R.
    Hilton, M.
    Abrey, L.
    Wick, W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S774 - S775
  • [4] AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
    Chinot, O. L.
    Wick, W.
    Saran, F.
    Mason, W. P.
    Henriksson, R.
    Nishikawa, R.
    Zeaiter, A. H.
    Moore, N.
    Das, A.
    Cloughesy, T. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM)
    Henriksson, Roger
    Bottomley, Andrew
    Mason, Warren
    Saran, Frank
    Wick, Wolfgang
    Nishikawa, Ryo
    Cloughesy, Timothy Francis
    Carpentier, Antoine F.
    Khe Hoang-Xuan
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba Ariela
    Hilton, Magalie
    Guijarro, Ana Maria Abajo
    Ravelo, Arliene
    Chinot, Oliver L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
    Chinot, O. L.
    Rouge, T. de la Motte
    Moore, N.
    Zeaiter, A.
    Das, A.
    Phillips, H.
    Modrusan, Z.
    Cloughesy, T.
    [J]. ADVANCES IN THERAPY, 2011, 28 (04) : 334 - 340
  • [7] AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
    O. L. Chinot
    T. de La Motte Rouge
    N. Moore
    A. Zeaiter
    A. Das
    H. Phillips
    Z. Modrusan
    T. Cloughesy
    [J]. Advances in Therapy, 2011, 28 : 334 - 340
  • [8] Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RI) in newly diagnosed glioblastoma: Final results from AVAglio
    Wick, W.
    Cloughesy, T.
    Henrikkson, R.
    Saran, F.
    Mason, W.
    Nishikawa, R.
    Hilton, M.
    Abrey, L.
    Chinot, O.
    [J]. ONKOLOGIE, 2013, 36 : 94 - 94
  • [9] Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AV Aglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM)
    Wick, Wolfgang
    Cloughesy, Timothy Francis
    Nishikawa, Ryo
    Mason, Warren
    Saran, Frank
    Henriksson, Roger
    Hilton, Magalie
    Kerloeguen, Yannick
    Chinot, Oliver L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURVIVAL (OS) IN AVAGLIO, A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB (BEV) PLUS RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Phillips, Heidi
    Sandmann, Thomas
    Li, Congfen
    Cloughesy, Timothy
    Chinot, Olivier L.
    Wick, Wolfgang
    Nishikawa, Ryo
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Lai, Albert
    Moore, Nicola
    Hegde, Priti
    Abrey, Lauren
    Bourgon, Richard
    Garcia, Josep
    Bais, Carlos
    [J]. NEURO-ONCOLOGY, 2014, 16
12345